Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Reveal Less popular Authentic Realities You Didn't Learn in School - 225 of the world’s best sandwiches
- 3Hezbollah claims right to respond to killing of top commander
- 4Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- 5More parents refusing this shot that prevents serious bleeding at birth
- Dominating the Remote Work Way of life: Individual Systems
- The best movies to watch this holiday season: Stream 'A Christmas Story Christmas,' revisit 'The Night Before' and discover 'The Baltimorons'
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- 5 Home Improvement Styles: Decision in favor of Your #1
- The Best Portable Applications for Emotional wellness and Prosperity
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
